ZGNX - Zogenix, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
47.81
+0.24 (+0.52%)
As of 10:01AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close47.56
Open47.87
Bid47.52 x 1000
Ask47.81 x 1200
Day's Range47.67 - 47.95
52 Week Range33.43 - 59.85
Volume6,498
Avg. Volume555,695
Market Cap2.029B
Beta (3Y Monthly)2.10
PE Ratio (TTM)N/A
EPS (TTM)-3.25
Earnings DateNov 6, 2017 - Nov 10, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est62.82
Trade prices are not sourced from all markets
  • Is Zogenix, Inc. (NASDAQ:ZGNX) A Financially Strong Company?
    Simply Wall St.yesterday

    Is Zogenix, Inc. (NASDAQ:ZGNX) A Financially Strong Company?

    Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like Zogenix, Inc...

  • Here's Why Zogenix Leaped 26.8% in June
    Motley Fool10 days ago

    Here's Why Zogenix Leaped 26.8% in June

    The company rebounded after remedying an embarrassing regulatory gaffe.

  • GlobeNewswire10 days ago

    Zogenix Completes Enrollment in Phase 3 Trial of FINTEPLA® in Lennox-Gastaut Syndrome

    Zogenix, Inc. (ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has completed enrollment for, and randomized the last patient into the treatment period of, Study 1601, the Company’s Phase 3 clinical trial of its lead investigational therapy, FINTEPLA® (ZX008, fenfluramine), for the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS), a severe and often treatment-resistant childhood-onset epilepsy. Study 1601 is a multi-national, randomized, double-blind, placebo-controlled trial of two fixed doses of FINTEPLA as adjunctive therapy for seizures in children and adults with LGS.  After establishing a baseline seizure frequency for four weeks, patients are randomized into one of three treatment groups (0.2 or 0.8 mg/kg/day FINTEPLA, maximum of 30 mg/day, or placebo) for a two-week period of dose titration before being held at a fixed dose for 12 weeks of maintenance treatment.  The study randomized a total of 263 patients, with approximately 87 subjects per group.  The primary endpoint of the clinical trial is the change in the number of seizures that result in drops between baseline and the combined titration and maintenance periods at the 0.8 mg/kg/day dose compared to placebo.  The key secondary endpoints include change in the number of drop seizures between baseline and the combined titration and maintenance periods at the 0.2 mg/kg/day dose compared to placebo, and the proportion of patients achieving a 50% reduction in drop seizures.  Patients who complete the maintenance treatment period may be eligible to enter a 12-month open-label extension to evaluate the long-term safety, tolerability and effectiveness of FINTEPLA in LGS.

  • 3 Hot Biotechs Trending Now
    TipRanks11 days ago

    3 Hot Biotechs Trending Now

    Biotech is a tough market to follow. Promising research avenues hit roadblocks, clinical trials can fail, and regulators can withhold approval. And all of that can happen to companies that frequently operate at a loss, with high initial overhead costs and a long road toward profitability.The rewards, however, are great. A new drug hitting the market, or news of a successful long-term trial, can bring in new investors and give a tremendous boost to a company’s shares. We’ve sorted through the data to find three biotechs that are making waves. These are mid- to large-cap firms, with new drugs in the pipeline or recently released, and high expectations for near-term returns. Amarin Corporation, Plc. (AMRN)Cardiac disease is a leading killer, and the American consumer is willing to pay a premium for cholesterol-reducing drugs of proven efficacy. Amarin has entered that niche with its sole product, Vascepa, a new drug based on Omega-3 fatty acids.You’ve heard of Omega-3, of course – it has been promoted for years as a dietary supplement for cardiovascular health. With Vascepa, Amarin has concentrated the active factors to create, not a supplement, but a hypertriglyceridemia drug for the specific treatment of high cholesterol. Vascepa was approved by the FDA in 2012, was promptly entered into the multi-year REDUCE-IT study, and in September 2018 Amarin announced the study results. In the controlled study of 8000 patients over six years, Vascepa showed significant results in preventing heart attacks. AMRN shares jumped from under $3 per share to over $15, and have held those gains.Now the company is looking to use its profits for expansion. Per Roth Capital’s Yasmeen Rahimi, “Amarin provided record revenue for the first half of 2019 for Vascepa, guided $380M-420M for 2019 and unveiled its plans to increase its U.S. sales team to about 800 in October 2019.” Rahimi sees this move as the beginning for Vascepa, heralding the drug’s conversion to a true money-maker for the Amarin. She gives the stock a $31 price target, suggesting an upside of 33%.Jefferies analyst Michael Yee agrees with the rosy outlook for Vascepa’s profit potential. He notes the “positive pre-announcement with upside Q2 sales beat and full-year guidance raise supporting the thesis of strong Vascepa launch and greater outlook and opportunity than consensus expectations.” Yee adds that he sees the stock moving higher to the upside on increases future sales. His price target, $30, implies a 29% potential for share price gains.Amarin has been doing well, on Vascepa’s strong reviews and success in the market. The stock has a unanimous analyst consensus of ‘Strong Buy,’ based on 6 buy ratings in the past three months. The average price target, $32, gives a 41% upside to the share price of $23.View AMRN Price Target & Analyst Ratings Detail Gilead Sciences, Inc. (GILD)Gilead is well-established in the pharma sector – it’s a major player on the American medical research scene, and holds a dominant position the HCV and HIV drug research segments. Casual consumers are more likely to encounter Gilead through its popular anti-viral drug Tamiflu, marketed as an OTC preventative and treatment for the flu.In recent development, Gilead has been moving filgotinib, a potential treatment for rheumatoid arthritis, forward in testing. Filgotinib is now if Phase III trials, and the company has announced that it will file a New Drug Application with the FDA – the next step in getting approval before marketing.Writing from RBC Capital, four-star analyst Brian Abrahams notes several factors that are boosting GILD stock. Filgotinib’s regulatory progress is prominent on the list. Abrahams also says that stock’s “valuation looks cheap and at a floor,” and points out the “strong balance sheet and solid dividend yield.”That last is an important point; most biotech firms do not pay any dividend, but Gilead initiated payments in 2015. The yield is now up to 3.68%, and payouts are $2.52 annualized, making it a strong incentive for investors. Abrahams’ price target on GILD, $91, indicates a 32% upside to the stock.Alethia Young, of Cantor Fitzgerald, has been following Gilead for several years, and had previously estimated that filgotinib would launch in the US in 2022 with initial sales up to $93 million. Citing the “positive" U.S. filing update,” she now believes that the timeline has moved up by at least one year and sees a potential approval in late 2020. She raised her price target on the stock to $88 to reflect her optimism.Gilead’s overall rating is a ‘Moderate Buy,’ based 13 buys, 5 holds, and 1 sell assigned during the past three months. The stock’s current share price is $68, and the average price target is $79; this gives GILD shares a 15% upside potential.View GILD Price Target & Analyst Ratings Detail Zogenix, Inc. (ZGNX)Like many smaller biotech research firms, Zogenix does not yet have a drug on the market. Unlike most such firms, however, Zogenix’ main research program is a reuse of a previously approved drug, fenfluramine. This was used in the past as a treatment for obesity; Zogenix has been researching its potential has a seizure treatment for children with the rare disease Dravet Syndrome. The studies have reached Phase III, and have shown some promise.The company’s stock took a hit, however, when the FDA last quarter ‘refused to file’ Zogenix’ application for fenfluramine as a new drug, branded Fintepla, for seizure treatment. ZGNX shares lost more than $10, and the company had to shift focus to bureaucratic streams.ZGNX got a boost last month, when the FDA reversed course. Regulators have said that they will permit the new drug application for Fintepla, and without additional preclinical toxicity data. According to Danielle Brill, pharma sector analyst from Piper Jaffray, this was the “best case scenario for Zogenix.” She says, “Although breakthrough therapy status was rescinded due to the recent approvals of two other drugs for Dravet Syndrome, expect an expedited review [with] approval and launch by Q2 of 2020. [Do] not expect the delay to have any meaningful impact on Fintepla's overall commercial potential.” She gives ZGNX shares a $64 price target, suggesting a 34% upside.Difei Yang, of Mizuho, also sees the FDA’s regulatory reversal as a win for Zogenix. She says, “A priority review is highly likely and the FDA's decision is a positive.” Yang bumped her price target up to $65, indicating confidence in a 36% upside.Zogenix’ upbeat regulatory outlook has given it support in the markets. Shares stand at $47, up $8 since the FDA decision. The average price target is $61, giving the stock a 28% upside potential. And like Amarin, the analysts are unanimous on ZGNX – 9 buy ratings give it a ‘Strong Buy’ consensus rating.View ZGNX Price Target and Analyst Ratings DetailVisit TipRanks’ Trending Stocks tool to see what else is hot in today’s markets.

  • GuruFocus.com12 days ago

    Zogenix Inc (ZGNX) President and CEO Stephen J Farr Sold $1.6 million of Shares

    President and CEO of Zogenix Inc (NASDAQ:ZGNX) Stephen J Farr sold 34,225 shares of ZGNX on 07/03/2019 at an average price of $48.01 a share.

  • Can This Biotech Stock Rival The First FDA-Approved Cannabis Medicine?
    Investor's Business Daily21 days ago

    Can This Biotech Stock Rival The First FDA-Approved Cannabis Medicine?

    Zogenix stock popped Thursday after the Food and Drug Administration said the biotech company can resubmit its application for a seizure treatment without running additional studies.

  • Here's Why Zogenix Shares Rose as Much as 23.8% Today
    Motley Fool21 days ago

    Here's Why Zogenix Shares Rose as Much as 23.8% Today

    The company cleared up an issue with the FDA.

  • Benzinga21 days ago

    Zogenix Secures FDA Approval For Resubmission Of Seizure Drug Application

    Zogenix, which focuses on developing rare disease therapies, said following the receipt of the minutes of a May 30 Type A meeting with the FDA, it plans to resubmit the NDA for Fintepla, its investigational asset for the treatment of seizures associated with Dravet syndrome, in the third quarter. The Type A meeting was scheduled after the FDA issued a Refusal to File letter April 5, citing two issues: non-submission of non-clinical studies and an incorrect version of a clinical dataset within the application. The FDA has agreed to the company's plan to resubmit the NDA without the inclusion of the new chronic toxicity studies requested by the agency.

  • GlobeNewswire21 days ago

    Zogenix Announces FDA Agreement to Proceed with Resubmission of FINTEPLA® NDA

    Zogenix, Inc. (ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that following receipt of final minutes from the U.S. Food and Drug Administration (FDA) from the Type A meeting held on May 30, 2019, the Company intends to resubmit its New Drug Application (NDA) for FINTEPLA® (ZX008, fenfluramine) for the treatment of seizures associated with Dravet syndrome in the third quarter of this year.

  • Zogenix, Inc.'s (NASDAQ:ZGNX) Shift From Loss To Profit
    Simply Wall St.last month

    Zogenix, Inc.'s (NASDAQ:ZGNX) Shift From Loss To Profit

    Zogenix, Inc.'s (NASDAQ:ZGNX): Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the...

  • Hedge Funds Have Never Been More Bullish On Zogenix, Inc. (ZGNX)
    Insider Monkeylast month

    Hedge Funds Have Never Been More Bullish On Zogenix, Inc. (ZGNX)

    Is Zogenix, Inc. (NASDAQ:ZGNX) a good bet right now? We like to analyze hedge fund sentiment before doing days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage of […]

  • ACCESSWIRElast month

    The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of EB, BE and ZGNX

    NEW YORK, NY / ACCESSWIRE / June 11, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have ...

  • GlobeNewswirelast month

    Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Zogenix, Inc.

    Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming June 11, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Zogenix, Inc. (“Zogenix” or the “Company”) (NASDAQ: ZGNX) investors who purchased securities between February 6, 2019 and April 8, 2019, inclusive (the “Class Period”). If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. On April 8, 2019, Zogenix announced that it received a refusal to file letter from the U.S. Food and Drug Administration (“FDA”) regarding Zogenix’s new drug application (“NDA”) for FINTEPLA, Zogenix’s proposed treatment for seizures associated with Dravet syndrome.

  • ACCESSWIRElast month

    The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ZGNX, XENT and CYH

    NEW YORK, NY / ACCESSWIRE / June 11, 2019 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders ...

  • ACCESSWIRElast month

    ZGNX, BV & TRNX - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Deadlines

    NEW YORK, NY / ACCESSWIRE / June 11, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. If you suffered a loss, you can request that the Court appoint you as lead plaintiff.

  • ACCESSWIRElast month

    CLASS ACTION UPDATE for ZGNX, BSX and JMIA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

    NEW YORK, NY / ACCESSWIRE / June 10, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders ...

  • ACCESSWIRElast month

    FINAL DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / June 10, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zogenix, Inc. ("Zogenix" ...

  • ACCESSWIRElast month

    Rosen, A Globally Recognized Law Firm: June 11 Deadline in Zogenix, Inc. in Securities Class Action - ZGNX

    NEW YORK, NY / ACCESSWIRE / June 10, 2019 / Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zogenix, Inc. (NASDAQ: ZGNX) from February 6, 2019 through April 8, ...

  • ACCESSWIRElast month

    FINAL DEADLINE TUESDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / June 8, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zogenix, Inc. ("Zogenix" ...

  • ACCESSWIRElast month

    SHAREHOLDER ALERT: ZGNX LYFT SCOR: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

    NEW YORK, NY / ACCESSWIRE / June 7, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have ...

  • ACCESSWIRElast month

    IMPORTANT DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / June 7, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zogenix, Inc. ("Zogenix" ...

  • ACCESSWIRElast month

    FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of WSR, ZGNX and XENT

    CEDARHURST, NY / ACCESSWIRE / June 7, 2019 / The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses. If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court.

  • GlobeNewswirelast month

    Zogenix, Inc. (ZGNX), BrightView Holdings, Inc. (BV) & Taronis Technologies, Inc. f/k/a MagneGas Applied Technology (TRNX) - Bronstein, Gewirtz & Grossman, LLC Notifies of Class Actions

    Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. If you suffered a loss, you can request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

  • ACCESSWIRElast month

    The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ZGNX, BSX and KSHB

    NEW YORK, NY / ACCESSWIRE / June 7, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have ...

  • GlobeNewswirelast month

    ZGNX ALERT:  Zhang Investor Law Reminds Investors of June 11 Deadline in Securities Class Action Lawsuit Against Zogenix, Inc. – ZGNX

    Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Zogenix, Inc. (ZGNX) from February 6, 2019 through April 8, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Zogenix investors under the federal securities laws. If you wish to serve as lead plaintiff, you must move the Court no later than June 11, 2019.